Company / Operating Income
Cardiff Oncology, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$49.0M
FY2025
5-year range
-$49.0M / -$19.1M
FY2021-FY2025
Trend
-7.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has declined for 4 consecutive years, from -$19M in FY2021 to -$49M in FY2025.
Based on SEC 10-K filings.
-$49M in FY2025.
Declined from -$40M to -$49M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cardiff Oncology, Inc.'s operating income has declined for 4 consecutive years.
- In FY2025, operating income decreased 7.8% year-over-year.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$49.0M | -7.8% |
| FY2024 | -$45.4M | -13.8% |
| FY2023 | -$39.9M | -38.3% |
| FY2022 | -$28.9M | -51.2% |
| FY2021 | -$19.1M | +0.0% |
| FY2020 | -$19.1M | -14.4% |
| FY2019 | -$16.7M | +34.8% |
| FY2018 | -$25.6M | +36.2% |
| FY2017 | -$40.1M | -168.6% |
| FY2016 | -$14.9M | +40.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026